方达控股(01521)公布，于2025年10月10日，该公司全资附属公司方达上海(作为买方)、杭州泰格(作为 销售股份I的卖方)及杭州泰格全资附属公司嘉兴欣格(作为销售股份II的卖方)订立股份转让协议，据此， 方达上海有条件同意收购，而杭州泰格及嘉兴欣格各自有条件同意出售销售股份(占目标公司上海观合 医药科技股份有限公司于完成回购及减资后的全部已发行股本)，代价总额为人民币2.7亿元。交割后， 目标公司将成为公司全资附属公司，而目标集团的财务业绩将综合入账至集团财务报表。 据悉，目标公司为一家于中国成立的股份有限公司，主要从事临床试验技术服务、临床试验相关服务及 化验室服务。无锡观合医学、观合医药香港为目标公司的全资附属公司，主要从事临床研究服务。 据董事所知，无锡观鹤、无锡观荷二期、无锡观和三期及无锡观禾四期均为目标公司僱员所拥有的持股 平台(统称"持股平台")。根据回购协议，目标公司将回购由持股平台所持的所有股份。回购股份其后将 被注销，导致目标公司的注册资本有所减少。截至本公告日期，回购及减资已根据适用的中国法律完成 公告期，预期将于2025年10月31日或之前正式完成。于回购及减资完成后，目标公司的注 ...

Group 1 - The company Fonda Holdings (01521) has entered into a share transfer agreement to acquire Shanghai Guanhua Medical Technology Co., Ltd. for a total consideration of RMB 270 million, which will make the target company a wholly-owned subsidiary after completion [1][2] - The acquisition aims to enhance the group's global laboratory service capabilities and strengthen its influence in China, as the target group is a leading provider of clinical research laboratory services with extensive experience in supporting over 1,500 clinical trials [2] - The target company's successful track record includes contributions to the successful launch of 35 new drugs and support for regulatory audits, which aligns well with the group's existing expertise [2] Group 2 - The target company primarily engages in clinical trial technology services, related services, and laboratory services, with its wholly-owned subsidiaries focusing on clinical research services [2] - Following the acquisition, the group's financial performance will be consolidated into its financial statements, and the registered capital of the target company will be reduced to RMB 45,169,326 after the buyback and capital reduction [1] - The acquisition is expected to be completed by October 31, 2025, and will further solidify the group's position as a trusted partner in the clinical research industry by enhancing its ability to provide high-quality one-stop services to pharmaceutical companies and research institutions [2]

Summary of the Conference Call for Tigermed (泰格医药) Company Overview - Tigermed is a leading clinical Contract Research Organization (CRO) in China, established in 2004, focusing on clinical trials and related services, including registration, medical writing, and pharmacovigilance [4][5]. Industry Insights - The domestic clinical CRO sector has shown significant performance improvements, driven by the recovery of demand for innovative drugs and the impact of favorable policies [3]. - The Chinese biopharmaceutical industry is entering a phase of original innovation, with increasing global recognition of domestic data and a higher proportion of external licensing pipelines [2][7]. Financial Performance - In the first half of 2024, Tigermed's revenue decreased by 3% year-on-year to 3.25 billion yuan, and non-recurring net profit fell by 67% to approximately 200 million yuan [2][6]. - Despite the decline, the impact of low-price orders is gradually dissipating, and a return to double-digit growth in revenue and profit is expected in the coming year [2][6]. Market Dynamics - The Chinese clinical CRO market is fragmented, with Tigermed holding a market share of approximately 13%, expected to rise to 15% [10]. - The demand for overseas orders, which typically offer higher profit margins, is crucial for sustaining growth in the second and third quarters [11]. Business Development - Tigermed has a broad project layout, with over 400 domestic projects and 200 international projects, primarily in the US, Japan, South Korea, and Australia [12][21]. - The company has seen a 7% year-on-year increase in new orders for 2024, with a continued acceleration in the first half of the year [22]. Strategic Initiatives - The company is expanding globally through acquisitions and the establishment of local teams, enhancing its service capabilities from clinical trials to imaging analysis [21]. - The domestic biopharmaceutical industry is experiencing a diversification of funding sources, with industrial funds and state-owned capital becoming significant players [9][8]. Future Outlook - The overall performance of the clinical trial services segment is expected to recover, with a projected increase in orders as early research in China rebounds [20][22]. - The company anticipates that the clinical CRO and early-stage CRO industries will show strong growth, contingent on the recovery of orders [22]. Additional Insights - The SMO (Site Management Organization) business has seen significant growth, although it faces some price competition and personnel surplus issues [17][18]. - The tree child business segment has been a strong contributor to profits, maintaining steady growth [16]. This summary encapsulates the key points from the conference call, highlighting Tigermed's current position, market dynamics, financial performance, and future outlook in the clinical CRO industry.

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 公 告 2025年 進一步變更H股發售所得款項用途 茲提述(i)杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司， 統 稱「本集團」）日 期 為2020年7月28日 的 招 股 章 程（「招股章程」），內 容 有 關 本 公 司 全 球 發 售（「全球發售」或「H股發售」）的 所 得 款 項 淨 額；(ii)本公司 日期為2020年8月6日 的 公 告，內 容 有 關 全 球 發 售 的 發 售 價 及 配 發 結 果； (iii)本公司日期為2020年8月31日 的 公 告， ...